Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations

被引：0
|
作者：
Heymach, John
Opdam, Frans
Barve, Minal
Tu, Hai-Yan
Wu, Yi-Long
Gibson, Neil
Sadrolhefazi, Behbood
Serra, Josep
Yoh, Kiyotaka
Yamamoto, Noboru
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT203
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT203
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety
    Feng Guo
    Stephen P. Letrent
    Pamela N. Munster
    Carolyn D. Britten
    Karen Gelmon
    Anthony W. Tolcher
    Amarnath Sharma
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 97 - 109
  • [32] A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
    Zhang, Jian
    Cao, Junning
    Li, Jin
    Zhang, Yifan
    Chen, Zhiyu
    Peng, Wei
    Sun, Si
    Zhao, Naiqing
    Wang, Jiachen
    Zhong, Dafang
    Zhang, Xiaofang
    Zhang, Jing
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [33] A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
    Jian Zhang
    Junning Cao
    Jin Li
    Yifan Zhang
    Zhiyu Chen
    Wei Peng
    Si Sun
    Naiqing Zhao
    Jiachen Wang
    Dafang Zhong
    Xiaofang Zhang
    Jing Zhang
    Journal of Hematology & Oncology, 7
  • [34] Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
    Moulder, Stacy L.
    Borges, Virginia F.
    Baetz, Tara
    Mcspadden, Tessa
    Fernetich, Gina
    Murthy, Rashmi K.
    Chavira, Renae
    Guthrie, Kari
    Barrett, Emma
    Chia, Stephen K.
    CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3529 - 3536
  • [35] A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies
    Filipa Lynce
    Hongkun Wang
    Emanuel F. Petricoin
    Paula R. Pohlmann
    Brandon Smaglo
    Jimmy Hwang
    Aiwu R. He
    Deepa S. Subramaniam
    John Deeken
    John Marshall
    Michael J. Pishvaian
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 1145 - 1151
  • [36] A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies
    Lynce, Filipa
    Wang, Hongkun
    Petricoin, Emanuel F.
    Pohlmann, Paula R.
    Smaglo, Brandon
    Hwang, Jimmy
    He, Aiwu R.
    Subramaniam, Deepa S.
    Deeken, John
    Marshall, John
    Pishvaian, Michael J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (05) : 1145 - 1151
  • [37] Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations
    Johnson, Melissa Lynne
    Soo, Ross A.
    Wu, Yi-Long
    Baktash, Navid
    Maier, Daniela
    Eigenbrod-Giese, Sabina
    Yoshida, Tatsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer
    Baird, R. D.
    Cresti, N.
    Beddowes, E.
    Saggese, M.
    Flynn, M.
    Corbacho, J. Garcia
    Gao, F.
    Lemech, C.
    Donaldson, K.
    Posner, J.
    Kawabata, I.
    Forster, M.
    Arkenau, H. T.
    Plummer, R.
    Jodrell, D.
    Spicer, J.
    CANCER RESEARCH, 2013, 73
  • [39] A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
    N. Haense
    A. Atmaca
    C. Pauligk
    K. Steinmetz
    F. Marmé
    G. M. Haag
    M. Rieger
    O. G. Ottmann
    P. Ruf
    H. Lindhofer
    S.-E. Al-Batran
    BMC Cancer, 16
  • [40] A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
    Zhang, Pin
    Wang, Lin
    Zhen, Yueying
    Wang, Zhihong
    Zhang, Hesheng
    Jones, Richard
    Xu, Binghe
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (01)
12345